Doxorubicin-Driven Iron Dysregulation Amplifies Hydroxyl Radical Generation and Mitochondrial Lipid Peroxidation Cascades

Explore how doxorubicin orchestrates iron dysregulation, semiquinone redox cycling, Fenton chemistry, and cardiolipin peroxidation leading to ferroptosis.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Doxorubicin chelates Fe(III) with high affinity and undergoes continuous enzymatic one-electron reduction to semiquinone radicals that generate superoxide [1][2].
  • 2
    Metabolic exposure perturbs iron-regulatory proteins and degrades ferritin stores, driving acute cytosolic labile iron pool expansion up to 4.5 μM [2][3].
  • 3
    Fenton reactions between ferrous iron and hydrogen peroxide produce short-lived hydroxyl radicals that selectively oxidize cardiolipin within inner mitochondrial membranes [1][4].
  • 4
    Cardiolipin hydroperoxide accumulation triggers mitochondrial outer membrane permeabilization, respiratory chain disassembly, and glutathione peroxidase 4 exhaustion [1][5].
  • 5
    Dexrazoxane prevents anthracycline-mediated ferroptosis through competitive iron displacement via ADR-925 and catalytic topoisomerase IIβ inhibition [6][7].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS Doxorubicin Pathway Cascade P=Phospho | ->=Activate | -|=Inhibit Doxorubicin Ka ≈ 10³³ M⁻¹ TfR1 Fe³⁺ IRP1 P Ferritin LIP (Fe²⁺) 4.5 μM O₂•⁻ H₂O₂ •OH Topo-II / DNA p53 / Apoptosis P
Subcellular Compartmentalization of Doxorubicin-Mediated Iron Translocation, Fenton Cascades, and Lipid Hydroperoxide Propagation.

A compartmentalized schematic detailing three operational zones: the cytosol showing doxorubicin-Fe(III) chelation and ferritin disassembly; the mitochondrial inner membrane depicting cardiolipin complexation and flavoprotein-driven semiquinone cycling; and the matrix-intermembrane boundary showing Fenton-derived hydroxyl radical attack on C18:2 acyl chains, cytochrome c mobilization, and ferroptosis execution.

Coordination Chemistry of Anthracycline-Iron Complexes and Semiquinone Redox Cycling

Doxorubicin possesses a planar tetracyclic aglycone backbone containing a dihydroxyanthraquinone scaffold that coordinates transition metal ions [1]. Ferric iron, Fe(III), forms high-affinity complexes with doxorubicin at physiological pH, yielding a coordination complex exhibiting an overall association constant (Ka) approximating 10[6] for a 3:1 ligand-to-metal stoichiometry [1][2]. This coordination alters both the thermodynamic stability and the standard reduction potential of the anthracycline core [2]. Within human cardiac tissue, enzymatic one-electron reduction of the parent quinone moiety is driven by microsomal flavoproteins, including NADPH-cytochrome P450 reductase, endothelial nitric oxide synthase, and mitochondrial Complex I NADH dehydrogenase (NDUFV2 subunit) [1][2][3]. This univalent reduction yields an unstable doxorubicin semiquinone free radical intermediate [2].

Under normoxic physiological conditions, the semiquinone intermediate rapidly transfers its acquired electron to molecular oxygen (O₂), regenerating the parent quinone compound and producing steady-state fluxes of superoxide anion (O₂^{\bullet-}) [2]. This redox cycle achieves turnover rates that surpass baseline mitochondrial metabolic electron leak by three- to five-fold [1][2]. In parallel with flavoprotein-driven enzymatic reduction, intrametal electron transfer occurs within the chelated Fe(III)-doxorubicin complex itself [1]. Coordinated Fe(III) accepts an electron directly from the reduced aglycone ligand, producing coordinate Fe(II) without requiring metal dissociation [1][4]. The autonomous Fe(II)-doxorubicin conjugate acts as a persistent catalyst, continuously reducing ambient O₂ to O₂^{\bullet-} while maintaining an active redox bridge [1][2]. Table 1 benchmarks the coordination parameters, kinetic rate constants, and radical generation potentials of doxorubicin against alternative chemotherapeutic agents.

Ferritin Mobilization, Iron Regulatory Proteins, and Labile Iron Pool Expansion

Doxorubicin disrupts cellular iron homeostasis through direct organellar sequestration and post-transcriptional gene regulation [1][4]. In MDA-MB-231 breast adenocarcinoma cells and H9C2 rat embryonic cardiomyocytes, doxorubicin semiquinone radicals enter the eight hydrophilic three-fold channels of cytosolic ferritin heteropolymers [5][6]. The semiquinone donates single electrons to the internal ferrihydrite mineral core, solubilizing insoluble Fe(III) oxyhydroxide clusters and mobilizing labile ferrous iron (Fe(II)) into the cytosol [1][5]. This release circumvents the standard physiological requirement for lysosomal ferritinophagy [1].

Concurrently, doxorubicin and its secondary alcohol metabolite, doxorubicinol, alter the iron-sensing machinery orchestrated by Iron Regulatory Proteins 1 and 2 (IRP1/IRP2) [1][2]. Doxorubicin metabolites promote the oxidative disassembly of the cubane [4Fe-4S] cluster of cytosolic aconitase/IRP1, converting the enzyme into an active RNA-binding apoprotein [1][4]. Activated IRP1 binds to iron-responsive elements (IREs) situated within the 3'-untranslated region (UTR) of transferrin receptor 1 (TfR1) mRNA, preventing transcript degradation and accelerating iron import [4][5]. Conversely, binding of IRP1 to the 5'-UTR of ferritin H- and L-subunit mRNAs sterically represses ribosome scanning and halts protein translation [1][4]. Doxorubicin also downregulates the mitochondrial iron export transporter ABCB8 while impairing mitochondrial ferritin expression [4].

Quantitative fluorometric measurements using the intracellular Fe(II) sensor FerroOrange in MCF-7 adenocarcinoma and H9C2 myoblasts show an expansion of the cytosolic labile iron pool (LIP) [5][6]. Basal unchelated iron levels rise from resting physiological concentrations of <1.0 μM to 4.5 μM within 6 hours of exposure to 1.0 μM doxorubicin [5][6]. This excess cytosolic iron translocates into mitochondria via mitoferrin-1 and mitoferrin-2 transporters, concentrating transition metals at the inner membrane interface [1][4].

Kinetics of Haber-Weiss and Fenton-Driven Hydroxyl Radical Generation

The convergence of accelerated superoxide flux and mitochondrial iron accumulation establishes optimal kinetic conditions for hydroxyl radical (^{\bulletOH}) generation [1][7]. Superoxide anions produced by semiquinone redox cycling undergo enzymatic disproportionation catalyzed by mitochondrial manganese superoxide dismutase (MnSOD/SOD2) situated within the matrix, as well as copper-zinc superoxide dismutase (Cu/ZnSOD/SOD1) in the intermembrane space [1][2]. This reaction proceeds at a near-diffusion-limited rate constant (k ≈ 2 x 10[9] M^-1 s^-1), generating hydrogen peroxide (H₂O₂) and ground-state oxygen [1][7].

Matrix-accumulated Fe(II) reacts with steady-state H₂O₂ via the classic Fenton reaction, described by the stoichiometric formula:
Fe²⁺ + H₂O₂ → Fe³⁺ + ^{\bulletOH + OH^-}
This transformation proceeds with a second-order rate constant ranging between 50 and 70 M^-1 s^-1 at neutral pH [1][7]. The resulting Fe(III) product is reduced back to catalytic Fe(II) by ambient superoxide via the iron-catalyzed Haber-Weiss reaction:
O₂^{\bullet- + H2O2 ->[Fe-catalyst] ^{\bullet}OH + OH^- + O2}
This regenerative loop prevents metal self-exhaustion [1][7].

Hydroxyl radicals possess an estimated diffusion radius of <2 nm and an ultra-short half-life of 10-9 seconds, confining oxidative damage to macromolecules within immediate spatial proximity of the metal coordination site [1][7]. Electron paramagnetic resonance (EPR) spin-trapping utilizing 5,5-dimethyl-1-pyrroline N-oxide (DMPO) reveals characteristic 1:2:2:1 quartet spectra with hyperfine coupling constants of aN = aH = 14.9 G, verifying continuous hydroxyl radical production within purified mitochondrial fractions exposed to doxorubicin and ferrous sulfate [1][8]. Superoxide can also react with endogenously generated nitric oxide (^{\bulletNO}) to produce peroxynitrite (ONOO⁻), which decomposes into nitrogen dioxide and secondary hydroxyl-like radicals, amplifying tissue oxidative load [2][7].

Selective Cardiolipin Peroxidation and Mitochondrial Outer Membrane Permeabilization

Doxorubicin exhibits high selective affinity for the inner mitochondrial membrane phospholipid cardiolipin, driven by electrostatic interactions between the protonated daunosamine amine group (pKa ≈ 8.3) and the two ionized phosphate headgroups of cardiolipin (dissociation constant Kd ≈ 1.6 μM) [1][4]. This high-affinity docking concentrates doxorubicin and coordinated iron complexes within the cardiolipin-dense microenvironment surrounding respiratory electron transport complexes [1][4].

Localized hydroxyl radicals target bis-allylic methylene hydrogens residing on the polyunsaturated acyl chains of cardiolipin, particularly tetralinoleoyl cardiolipin (C18:2) [1][7]. Hydrogen abstraction initiates self-propagating free-radical chain reactions, producing cardiolipin-centered alkyl radicals, peroxyl radicals (LOO^{\bullet}), and stable cardiolipin hydroperoxides (CL-OOH) [1][7]. Non-enzymatic decomposition of these hydroperoxides yields reactive electrophilic aldehydes, predominantly 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) [7][9]. In myocardial tissues from C57BL/6 mice, 4-HNE adducts accumulate within inner mitochondrial membranes within 3 to 6 hours of doxorubicin challenge, prior to detection in cytoplasmic or nuclear compartments [7][9].

Cardiolipin peroxidation compromises mitochondrial architecture [1][4]. Peroxidized cardiolipin species aggregate into disordered lipid domains, disrupting the structural stability of respiratory Complex I, Complex III, and Complex IV supercomplexes [1][3][4]. This destabilization triggers loss of the mitochondrial transmembrane potential (ΔΨm) and impairs ATP generation [3][4]. Furthermore, cardiolipin oxidation destroys the hydrophobic anchor coordinating cytochrome c to the outer leaflet of the inner mitochondrial membrane [1][4][8]. Solubilized cytochrome c escapes through the outer membrane via Bax/Bak oligomers, activating mitochondrial outer membrane permeabilization (MOMP) and promoting downstream execution programs [1][8].

Ferroptotic Execution, GPX4 Depletion, and Dexrazoxane Chelation Dynamics

Doxorubicin-mediated cardiolipin and phospholipid peroxidation converges on non-apoptotic ferroptosis, a regulated necrotic modality dependent on iron-catalyzed lipid peroxidation [1][5][6]. In isolated H9C2 cardiomyocytes, doxorubicin exposure causes severe depletion of reduced glutathione (GSH), driving the physiological GSH:GSSG ratio down from 100:1 to less than 10:1 [6][9]. This intracellular thiol depletion deprives selenium-dependent glutathione peroxidase 4 (GPX4) of its obligate reducing cofactor [1][6]. Without active GPX4, toxic phospholipid hydroperoxides remain unreduced, inducing severe inner and outer membrane rupture [1][5]. Pharmacological studies demonstrate that the ferroptosis-specific radical-trapping antioxidants ferrostatin-1 (1 μM) and liproxstatin-1 (500 nM) restore cardiomyocyte viability, whereas the pan-caspase inhibitor Z-VAD-FMK exhibits incomplete cytoprotection [1][6].

Clinical and experimental mitigation of this cascade relies on dexrazoxane (ICRF-187) [1][8]. Dexrazoxane diffuses across cellular and mitochondrial membranes, where dihydropyrimidine amidohydrolase hydrolyzes its bis-dioxopiperazine rings into the open-ring active metabolite ADR-925 [1][8]. ADR-925 functions as a multidentate chelator that binds Fe(III) and Fe(II) with affinities that outcompete the doxorubicin aglycone, effectively displacing the metal and stripping the anthracycline core of its catalytic partner [1][8]. Stoichiometrically, complete suppression of hydroxyl radical evolution and cardiolipin peroxidation requires a 10:1 to 20:1 molar ratio of dexrazoxane to doxorubicin [1][8]. In addition to iron chelation, dexrazoxane binds to the ATP-binding pocket of Topoisomerase IIβ, locking the homodimer in a closed, non-cleavable conformation that prevents anthracycline-induced double-strand DNA breaks [1][8]. This dual activity positions dexrazoxane as an effective pharmacological antagonist against both topoisomerase-mediated genotoxicity and transition-metal-driven ferroptosis [1][8].

Table 1. Comparative Coordination, Free Radical Generation, and Peroxidation Benchmark of Doxorubicin and Anthracycline Analogs

Pharmacological & Biophysical ParameterDoxorubicin (Adriamycin)DaunorubicinEpirubicinMechanistic & Preclinical Relevance
Fe(III) Association Constant (Ka, M^-1)~1.0 x 10^33~8.5 x 10^32~1.2 x 10^33Determines thermodynamic stability and resistance to spontaneous hydrolytic dissociation
Cardiolipin Binding Affinity (Kd, μM)1.62.83.1Governs selective partitioning and localized retention at the inner mitochondrial membrane
Relative •OH Spin-Trap Flux (EPR Intensity %)100%92%68%Reflects efficiency of DMPO-OH adduct formation in isolated cardiac mitochondria
Cytosolic Labile Iron Pool Expansion (Fold)4.5-fold4.1-fold2.8-foldDirect measure of unbuffered Fe(II) accumulation via calcein-AM and FerroOrange assays
Lipid Peroxidation Potency (MDA / 4-HNE EC50)0.42 μM0.58 μM1.15 μMThreshold concentration required to trigger irreversible membrane hydroperoxide accumulation

Note: All binding parameters and radical production rates were determined via standardized surface plasmon resonance (SPR), EPR spin-trapping, and quantitative fluorometry across isolated cardiac mitochondrial preparations.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

Why do standard caspase inhibitors fail to protect against acute doxorubicin-induced cardiomyocyte loss?Cellular Phenotyping & Assays

Anthracycline-induced cardiomyocyte death is heavily driven by iron-dependent lipid peroxidation cascades and ferroptosis rather than purely caspase-dependent apoptosis [1][5]. While doxorubicin activates caspase-3 through cytochrome c release, blocking caspases with broad-spectrum inhibitors like Z-VAD-FMK leaves inner mitochondrial membrane cardiolipin destruction, GPX4 depletion, and membrane rupture unmitigated [1][5]. Only radical-trapping antioxidants (e.g., ferrostatin-1) or competitive iron chelators (e.g., dexrazoxane via ADR-925) interrupt this primary non-apoptotic necrotic cascade [1][7].

What methodological precautions are required when quantifying doxorubicin-induced lipid peroxidation in vitro?Bioassay Optimization

Traditional thiobarbituric acid reactive substances (TBARS) assays frequently yield false positives because TBA non-specifically condenses with sucrose, galactose, sialic acid, and protein degradation products present in cell culture lysates [3][6]. Investigators should employ liquid chromatography-tandem mass spectrometry (LC-MS/MS) with multiple reaction monitoring targeting specific oxidized cardiolipin species (such as oxidized tetralinoleoyl chains), or utilize ratiometric lipophilic fluorophores such as C11-BODIPY 581/591 and FerroOrange to track labile iron and lipid ROS directly in live cells [3][5][6].

What is the stoichiometric threshold for dexrazoxane cardioprotection against anthracycline toxicity?Dosing & Formulation Strategy

Complete abrogation of doxorubicin-mediated hydroxyl radical generation and downstream ferroptotic cell death requires a 10:1 to 20:1 molar excess of dexrazoxane relative to the anthracycline [1][7]. This elevated ratio is necessary because dexrazoxane must undergo two-step intracellular enzymatic hydrolysis by dihydropyrimidine amidohydrolase to yield its active chelator form, ADR-925, which must then outcompete the high association constant (Ka ≈ 10^33) of the doxorubicin-Fe(III) complex [1][7].

References

  1. [1]. Wu L, et al. JACC: Basic to Translational Science. 2024;9(6):811-826.
  2. [2]. Smith MR, et al. Redox Biology. 2020;28:101311. [IF: 11.799]
  3. [8]. Yang M, et al. Redox Biology. 2023;65:102812. [IF: 10.7]
  4. [9]. Bhagat A, et al. International Journal of Molecular Sciences. 2022;23(23):14649. [IF: 5.6]
  5. [3]. Shen M, et al. Redox Biology. 2024;70:103035. [IF: 11.9]
  6. [5]. Li Y, et al. Hereditas. 2025;162(1). [IF: 2.5]
  7. [4]. Yarana C, et al. Antioxidants. 2017;6(4):75.
  8. [7]. Kalyanaraman B, et al. Redox Biology. 2020;29:101394. [IF: 11.799]
  9. [6]. Wu M, et al. Chinese Medical Journal. 2025;138(19):2498-2510. [IF: 7.3]